691
www.praktickelekarenstvi.cz550715901901162343533734615075796446977287978629369681044111011831228130213851441149115661598162416941761
e1897617148020186169253
PRAKTICKÉ80737159019080160258338422459552632710
LÉKÁRENSTVÍ88197159019074149229330411488590663741833870
AKTUÁLNÍ71882940227122239349476597693822881
FARMAKOTERAPIE81062940227100218330490615733863967106811841312142214781582
Postavení6211508018858129185240303362416488517
pioglitazonu675450801886088158227280310365427486553624695
v7475508018866
moderní7568508018893163232287348420449
léčbě8043508018853108168230285
diabetes835550801886897166227282339394453
mellitus8835508018894148202256285340411466
2.932850801885783
typu9436508018854122183253
ditu550970019087118166249
u834970019089
pacientů958970019092164234265340424469552
s1545970019064
DM216449700190108230305
a1984970019077
tyto2096970019054128181262
přípravky2393970019093138170255301373441508582
jsou301097001903894178261
v3306970019077
rámci3418970019052123252322352
doporučení3806970019091174261346392476546618702732
tlačeny457397001905486155225298381447
na5501190019086156
přední7411190019086131205292375406
místa118211900190128159215264336
v15531190019070
léčbě,16581190019031107178264341364
nelze20571190019084160192255329
zapomínat24211190019062135221306435466549619665
i31211190019031
na31871190019084154
lety33761190019032107155228
prověřený36401190019086131213282356399473556622
pioglitazon,42971190019086118201288319350397469533614698724
který5501410019068120193237312
má89714100190125195
k11271410019062
dispozici12231410019082113168253338398430499529
rovněž17871410019042123192277352415
data22371410019082151197268
o25401410019079
příznivém26541410019083128160222306337407481610
ovlivnění32981410019080149182212282367443525556
kardiovaskulárních3888141001906313518026329337644551657363772075282186595098010491131
komplikací,5501630019068150281367400431496570641672697
ale12821630019085117194
také15111630019061133199274
disponuje182016300190100131187273359444526558634
daty24901630019099170216290
o28161630019097
příznivém294816300190101147179242328359430505634
ovlivnění36181630019097167200231302388465548579
jednotlivých42331630019046122210293378425457487559634703787
složek550185001906091174235309375
metabolického96018500190127203250322408493526556625690764848932
syndromu,19271850019056126212297342423553635660
což26221850019067148209
tento28661850019045119202247328
efekt32291850019073113188254307
pochopitelně35711850019084169240323407494526574647679761837
umocňu‑44441850019080209293364447529576
je.5220970019034110134
Nelze53899700190110186218281355
rovněž5779970019055136205290366430
podceňovat6244970019096181268338411494577647718764
jeho7043970019042118201285
vliv7363970019080113143214
na7612970019093163
zlepšení7810970019072105181267324400483514
inzulínové8359970019041124187271302333416499569643
rezistence,9037970019055129193225281330403487557630653
ochranný52201190019085156239284356439522588
vliv58431190019078111141212
na60901190019091161
endotel62861190019084167253336382456488
a68091190019078
B‑buňky.69221190019087136224308390455530548
Navíc750511900190108178247279348
je78881190019040115
pioglitazon80391190019094125209295327357405476540621705
nyní87791190019092158243274
dostupný90881190019093176233283366452536602
i52201410019033
ve52881410019075149
formě54721410019044127172302379
generických58861410019089165248324369401471536610678761
preparátů,66821410019091136210296368412484530613638
což73551410019073154215
dále76051410019089159191266
léčbu79061410019036112183269352
zlevňuje.8293141001906799175245330412443519543
V88711410019083
neposlední89891410019088165251336393424500587670700
řadě52201630019047119204280
byla55351630019096164197266
zmírněna58361630019072202233277362438521591
i64621630019041
preskripční65381630019096141215273337385417503574657687
omezení,72601630019093222299363437520551576
která78711630019075128201246317
nyní82231630019094160245275
neobsahují85331630019093170255341399471554636668698
hranici92661630019093138210293323393423
HbA1c,522018500190101187276339400426
doporučenou56811850019087170257342388472541614697781865
k65811850019067
zahájení66831850019065138221291323398482512
léčby.72301850019034110181266334352
LITERATURA5522245020884132225317418533615733834949
1.550247601576685
LowWang6632478015553119210339393460529
CC,12192478015569136157
Hess14042478015576138184230
CN,16612478015569149169
Hiatt18582478015577101157194236
WR,212224780155101165188
et2338247801555795
al.2461247801555479100
Clinical2589247801556993118184209264322347
update:29642478015563132202258295354374
cardiovascular33662478015552110146212237304360417463519585610666702
disease4096247801556590135196252297359
in4482247801552389
diabetes4599247801556690146215277315374420
mellitus:55026380155106169195220245284351397417
atherosclerotic996263801556299167229266332379436461523560626664689745
cardiovascular17702638015561119156223249316373431477534602627684720
disease2519263801557499144206263309371
and29192638015562129199
heart31462638015573135192228271
failure3446263801553796121146213249310
in3784263801553098
type39102638015543104175238
241772638015566
diabetes4272263801557399155225288327386433
melli‑473426380155109172198223248286
tus5502798015540106150
–7282798015559
mechanisms,81527980155100161217284339405430474576621641
management,148427980155100156222278346407509570636672693
and22052798015553119187
clinical2420279801555277101167191246303328
considerations.27752798015553117184228252320380416473509534600667712734
Circulation3536279801556893128181247272327364388454521
2016;133:2459-2502.40852798015558117171224243294345402419480534591646687739800859916935
2.550295601576793
DeFronzo6712958015580143202235301369421487
RA.11862958015562139163
Insulin1378295801552390136202228252320
resistance,1726295801553494141166211251309377433493512
lipotoxicity,2266295801552448118187225290343369426451489549564
type2858295801553696167231
231172958015559
diabetes3205295801556691147217280319378425
and36592958015554122191
atherosclerosis:3879295801555492160222258324371428453515551617664688734754
the46612958015536104166
mi‑485529580155103128165
ssing550311801554895119187257
links:835311801552852120173224244
the11083118015540108170
Claude13063118015575100157224293355
Bernard16903118015565128164233290327394
Lecture21133118015558119177219286323383
2009.25253118015563123188250268
Diabetologia.28213118015584110167237300338404431499569594651673
2010;53:1270-1287.35223118015564124180235256318376394446498556614656710762821879887
3.550327601576691
UK6683278015576138
Prospective834327801556095160206275337394436461518578
Diabetes14393278015579105160229292330389435
Study1902327801555590157226282
(UKPDS)22113278015530108170235314371403
Group.26423278015576113178245314334
Intensive3003327801552390126185252297321378438
blood‑glucose3469327801556692159228298336408433499555619665727
control42233278015553118186222258324350
with46013278015588114152219
sul‑48483278015543109134172
phonylureas5503438015572140209277331358425461521578624
or12023438015574112
insulin1342343801553299145211237262329
compared17003438015562128233303362398458529
with22573438015599125164232
conventional25173438015563129197252313381418443511580637662
treatment3208343801554582142198236341403471508
and37443438015564132201
risk3974343801554369115167
of41703438015574107
complications43053438015563128234303330355411470507533600669715
in550359801552795
patients6733598015572130168193255323360408
with11103598015594120158226
type13653598015540100172235
216283598015564
diabetes1720359801557196153223286324384431
(UKPDS21793598015535114177242323381
33).25883598015564122150167
Lancet.27843598015558118185242302340362
1998;352:837-853.31753598015563115178240260322380439459521581637669733793851871
4.550375601576792
Stratton6703759015568104141200237280345414
IM,11123759015535135157
Adler12973759015584152178240276
AI,16023759015583109129
Neil17603759015590153178203
HA,19923759015589163186
et22073759015570109
al.2344375901556793114
Association24863759015584133179247305331387424450518586
of31013759015576109
glycaemia32393759015578104160215273335440465522
with378937590155101128166234
macrovascular405237590155114171228265331387445492549616642699735
and48153759015567135204
microvascular55039180155106131187223289344402448505571597653689
complications12673918015553118223292318343399457494519586654699
of1994391801556597
type2119391801553695166229
223763918015559
diabetes2463391801556691146216279317376422
(UKPDS29133918015530108171236316373
35):33143918015559117147166
prospective35083918015567104170216285347405447472529589
observational41253918015564135181242279340398435460527595652677
stu‑4830391801554484151190
dy.5504078015571127142
BMJ.7214078015566165210231
2000;321:405-412.9804078015563124188253274336393448461522586646684750802854875
5.550423601576791
Saltiel6694238015556115140179204266292
AR,9904238015571135158
Olefsky11774238015583110172204253305366
JM.15714238015541140163
Thiazolidinediones17624238015556127152208260326353378447472540602672698765834896943
in2733423801552390
the28524238015536104166
treatment3046423801553673133189227332394462499
of3573423801556598
insulin3699423801552391137203228253320
resistance4048423801553494141166211251309377434493
and45704238015554122192
type4790423801553696167230
II550439801552753
diabetes.631439801557196153223286324384431453
Diabetes.11134398015584110167236300338398445467
199616094398015563116178242
Dec;45(12):1661-9.18794398015584147205226288346375431483513532584638702754785847865
doi:27724398015571139165184
10.2337/diab.45.29854398015563118139203265323379412475500557627647708766785
12.37994398015563115135
1661.39634398015563117181233248
6.550455601576793
DeFronzo6714558015589152210244310379430496
RA,11964558015570147171
Inzucchi1395455801553299151219276330398423
S,1847455801556485
Abdul‑Ghani19604558015581151222289314353437506563630655
M,264445580155105128
Nissen28004558015587113158205267335
SE.31634558015565122143
Pioglitazone:3335455801556993161232257282321379431497566628648
The40124558015564135197
forgotten,42374558015539106143211279316359419486507
cost‑47734558015562127174214247
‑effective5504719015539104137172233291334359417477
cardioprotective10564719015558116152220245313384421487525584642685710768828
drug19134719015571107175245
for21864719015534101139
type23534719015540100172235
226164719015564
diabetes.2708471901557196153223286324384431453
Diab31904719015584110167236
Vasc34554719015566121167224
Dis37084719015584110155
Res.38924719015566128175197
2019;16:133-143.41184719015563123179232253305359379431483541579632687744764
7.550487601576779
Goldberg6574879015580150176246315379415483
RB,11694879015564129149
Kendall13474879015563124192262319344369
DM,17454879015583182204
Deeg19784879015583146209279
MA,228648790155100175198
et25134879015562100
al.;2642487901555783104125
GLAI27954879015580137215240
Study3064487901555995162232289
Investigators.3381487901552694149210256297322391449486551589637659
A40684879015575
comparison41724879015556122227297355392418463532600
of48014879015568101
li‑493048790155265190
pid550503901557298167
and7465039015560127197
glycemic972503901557197153209268373398454
effects1455503901556498133194252294343
of18265039015570103
pioglitazone1958503901557399166237263288326384437503571633
and26205039015560128197
rosiglitazone28465039015539106152177246272296335393445512580642
in3517503901552896
patients36415039015573131169194256324361409
with40795039015595121160228
type43355039015542102173236
246005039015565
diabe‑4693503901557297154223287327
tes5505199015540100147
and7255199015559127197
dyslipidemia.9505199015571127175200225294320390452556581638660
Diabetes16385199015584110167237300339398445
Care.21125199015574132168229248
2005;28:1547-1554.23895199015563123188248265327387407458511573629661714766823886906
8.550535601576794
Alam6725359015577103160264
F,965535901556168
Islam106153590155287499156260
MA,135053590155102177200
Mohamed157953590155102170239296400463533
M,214153590155102124
et22935359015564102
al.2424535901556085106
Efficacy2559535901556191124157214272329389
and29765359015560128197
Safety32025359015561119151213251311
of35425359015569102
Pioglitazone3673535901556690157228254278317375427494562624
Monotherapy432653590155102170239307345413475511570639695
in550551901552795
Type6735519015561109180244
29455519015564
Diabetes10385519015584111167237300339398445
Mellitus:151255190155102164190215240279346392412
A19535519015577
Systematic20585519015561113160201260365422460485542
Review26285519015566129186212273366
and30225519015560127197
Meta‑Analysis324855190155101164202260299373441498524580627652697
of39745519015570103
Randomised41055519015566124192262330435460506568639
Con‑47725519015575141209248
trolled550567901554077143170195257328
Trials.906567901556189115172197242265
Sci11995679015561118143
Rep.13705679015566128198219
2019;9:5389.16175679015563124179232253316338400458519580597
9.550583601576688
DeFronzo6665838015580142200234299367419484
RA,11795838015561137161
Tripathy1368583801555684110179237274341395
D,1791583801557996
Schwenke19155838015556113180270331398451511
DC,24545838015579153174
et2656583801555997
al.2781583801555480100
Pioglitazone2910583801556084151221247271310367419485553615
for3553583801552996133
diabetes3714583801556691147216279317377423
prevention41655838015567104164221281348385410477545
in4739583801552289
im‑48575838015522126163
paired5505998015572130155192252323
glucose901599801557196163220285332394
tolerance.13245998015540105132194230289357413473493
New18455998015583145237
Engl21115998015560128197223
J23625998015545
Med.243659980155101163234255
2011;364:1104-1115.27205998015563124179227238300362427446498545600665705759806853905925
10.5506156015767126151
Deeg7296158015583146209280
MA,103761580155100175199
Buse12646158015564132178240
JB,15326158015544108129
Goldberg16896158015580149176245315378415483
RB,22006158015564129150
et23786158015562100
al.;2507615801555783104125
GLAI26606158015580137215240
Study2929615801555895162232288
Investigators.3246615801552693149209256296322391448486551588636659
Pioglitazone3933615801556488156226252277315374426492560623
and45846158015558125195
rosi‑48086158015536103149174212
glitazone550631901557196121160218270336405467
have10456319015571128184244
different1318631901557197131166227263323391428
effects1775631901556497132193251294342
on21466319015570138
serum23136319015549111148216321
lipoprotein2662631901552953123192263300367404464489556
particle32476319015573131167211236293318380
concentrations36556319015559125193250310378414451510547573640709755
and44386319015560128198
sizes4664631901555074125186233
in4925631901552895
patients5506479015572130168193255323359408
with9876479015594120158226
type12426479015540100172235
215056479015564
diabetes1597647901557196153223286324384431
and20566479015559127197
dyslipidemia.22816479015571127175200225295321390452556582638660
Diabetes29696479015585111167237300339398445
Care.34436479015574132168229248
2007;30:2458-2464.37206479015563124188246260322384405468524581642681735791856921941
11.5506636015766117136
https://www.ema.europa.eu/en/documents/product‑information/pioglitazone‑actavis­7146638015564101142212257277324357448543638654715818875896957102310581123119312501272133313991444149815651610167217381795186219652026209321292177222122862323238824582523257926212653267927462777284328792984304030773101316832353280334633713438350735323556359436513702376838353896393639924048408941464201422742714306
‑epar‑product‑information_cs.pdf522024780155391041742322683023744114775486146717147477748418739409781083114111781203127113401406146415131536160716781711
12.52202636015767123150
Mazzone539926380155110168221276343412474
T,5902263801557083
Meyer601426380155110173229290327
PM,63692638015575172195
Feinstein65922638015570130156223270310370395463
SB,70832638015570133154
et72652638015573111
al.7405263801556995116
Effect75502638015570102138199257299
of78782638015579112
pioglitazone80182638015582108176247273298337395447514582645
compared86922638015567133239309367404464535
with925626380155103130169237
gli‑95222638015580106131168
mepiride522027980155106169239265301327396458
on57072798015568137
carotid58732798015557115152218255281350
intima‑media6252279801552694131156260318357463525596621677
thickness69582798015540108133189242312374421468
in7454279801552794
type7577279801553999171234
278402798015563
diabetes:7931279801557095152222285324383430450
a84102798015558
randomized8497279801553896164234302407432483544614
trial.9140279801553976102159185206
JAMA.93742798015544116216291316
2006;296:2572-2581.522029580155631241882522723343944584785406026617227578118739339891003
13.52203116015767123148
Koshiyama53963119015567133180247272329387491549
H,59733119015583104
Shimono61063119015561129154258326395463
D,65983119015585102
Kuwamura67293119015566132224282387454490548
N,73063119015584105
et74403119015564102
al.7571311901556086107
Rapid77063119015567125195221291
communication:80253119015559125230335402469494551609646672739808828
inhibitory8881311901552896164189258284323389426487
effect9396311901556598133194252294
of52203279015569102
pioglitazone5351327901557197165236261286325383435501570632
on60113279015569138
carotid61773279015558117153219257282352
arterial6557327901555995138198235261317343
wall69283279015594152178203
thickness71593279015540108133190243313375422469
in7656327901552795
type77793279015540100172235
280423279015564
diabetes.8134327901557196152222285324384431453
J86163279015544
Clin8689327901557499124191
Endocrinol89093279015560127197265323360386453521548
Me‑948632790155101163204
tab.5220343901554098168188
2001;86:3452-3456.54373439015563124188244256318381401464527585643678735798856916938
14.52203596015766124149
Nissen53973598015578103148194256323
SE,57483598015556112134
Nicholls59103598015578103159226293320344389
SJ,6327359801555698117
Wolski647235980155102166192237289317
K,6817359801556084
et6929359801555897
al.7054359801555479100
Comparison71823598015569134239308366402428473541609
of7819359801556497
pioglitazone7944359801556792160230255279318375427493561622
vs85943598015554101
glimepiride8723359801556691116219281350376412438506568
on93193598015564132
pro‑94793598015567104170211
gression52203758015571107167214261285353422
of56703758015571104
coronary58023758015560125162229297354391451
atherosclerosis6282375801556098166228264331377434460522558624671696741
in7052375801552896
patients71763758015574132169195256324361410
with76143758015596122161229
type78713758015542102173237
281363758015565
diabetes:8230375801557297154223287325385432452
the87113758015541109171
PERISCOPE89113758015567124187213270343424488545
ran‑9485375801553998166205
domized52203918015571139244269320381451
controlled57003918015558123192229266332359384446516
trial.6245391801554077103160185206
JAMA.64803918015545116216291316
2008;299:1561-1573.68243918015564124189252272334394457478530582643695727780833891952972
15.52204076015767123148
Nishio53954079015591116162229254322
K,5745407901557297
Sakurai58704079015568126180248284342368
M,626640790155109131
Kusuyama64254079015572138184250307365470527
T,6981407901556780
et70904079015570109
al.7227407901556792114
A73694079015583
randomized74814079015546104172242310415440491552622
comparison81324079015565131236306364401427472540609
of87694079015577110
pioglitazone89084079015579105172243269293332390442509577639
to95764079015547113
inhibit5220423901552795162187257283322
restenosis55704239015542102149189249317385432456502
after6100423901556295139198235
coronary63634239015561127164230299356392453
stenting6844423901555292152220257282350419
in7292423901553097
patients74184239015575133171196258326363411
with78584239015597123162230
type81164239015543103175238
283834239015566
diabetes.8478423901557399155225288327386433456
Diabetes89624239015588114170240303342401448
Care.94394239015577135172232252
2006;29:101-106.52204399015563124188252272334394416468523578610663718782804
16.52204556015767126152
Patel54004559015568124162221248
D,56764559015587104
Walitt580845590155109164190215254296
B,6133455901556888
Lindsay6250455901556186154224269328382
J,6661455901554767
Wilensky675645590155109136162223291337390450
RL.72354559015568125148
Role74114559015569137164225
of76654559015571104
pioglitazone77984559015574100168239264289328386438504573635
in8461455901553097
the85874559015542111173
prevention87884559015574112172229290357394420488556
of93734559015571104
res‑95064559015540101148184
tenosis52204719015540100168236283307353
and56014719015561129198
need58284719015572134197267
for61244719015536103140
revascularization62934719015540100157216262319386412469505531582642679705772841
after7162471901556194138197234
bare‑metal74244719015574132169229269376438476534560
stent8013471901555090150218255
implantation:82964719015529133203230287355391450487512580649668
a89934719015561
meta‑analy‑908247190155109171209267306363431488514570608
sis.5220487901554873119141
J53904879015544
Am54634879015576181
Coll56724879015574140167192
Cardiol58924879015574133169237262330356
Intv.6277487901552795132193208
2011;4:353-360.65144879015563123179226238300319382440498536593654717738
17.52205036015766120132
Althouse5380503801557196134201268335380442
AD,58495038015571152169
Abbott60465038015570140209278315357
JD,64305038015540122138
Sutton‑Tyrrell65965038015555121159201265333371423470507544603629653
K,7277503801555984
et7388503801555896
al.751250380155547999
Favorable76395038015555105160226262320389415476
effects8143503801555890125185242284332
of8503503801556396
insulin8627503801552288133199223248314
sensitizers89695038015543105171217240279303354413449496
per‑94935038015566129164197
tinent5220519801554065133195262299
to55475198015536101
peripheral56775198015567130166192262330392429487513
arterial6218519801555491134193230256312337
disease6584519801556691136198254300362
in6975519801552290
type7093519801553696167230
273515198015559
diabetes:7438519801556792148218281319379425445
results7912519801553494141206232270319
from8259519801553068134239
the85265198015536104166
Bypass87205198015561118189247294340
Angioplasty90885198015572140209234302372399455501542601
Revascularization52205358015565127184242288345411437493529555606665702727795863
Investigation6111535801552390145205252292317386443480505572640
267805358015558
Diabetes68675358015579105161230293332391437
(BARI7333535801553093165229255
2D)76165358015559139168
trial.781353580155357298154179200
Diabetes80415358015580106162231294332391438
Care.85075358015570128164224243
2013;36:3269-3275.87785358015559119174226244306366386449505564624665721778836893912
18.52205516015767125152
Dormandy54005518015584153190296353421490547
JA,59755518015544115139
Betteridge61425518015565128166209268305331400470532
DJ,67025518015583122141
Schernthaner68725518015559116184246282351388456513581643680
G,75805518015580103
et77115518015562101
al.7840551801555884105
PROactive79735518015565127213270327369395452513
investigators.8515551801552693148209256296322391448485551588636658
Impact92025518015526131201259316358
of95895518015568101
peripheral52205678015572135172198267336398435493519
arterial57675678015566102146205242268324350
disease61455678015578103148211267313375
in65495678015534101
patients66795678015578136174199261329366414
with712256780155100126165233
diabetes73845678015577102159229292330390437
–78495678015572
results79505678015545105152218243282331
from8309567801554179145251
PROactive85885678015572134220278335377402460521
(PROactive91375678015541104167253310367409435492553
11).52205839015563111134151
Atherosclerosis.54005839015576112180242279345391448474536572639685710755778
2009;202:272-281.62065839015564124189251272334394452473535593654689743803859873
19.52205996015767124146
Dormandy53945998015580149187292349417487543
JA,59665998015540111135
Charbonnel61305998015569137194230301370439506569595
B,6753599801556182
Eckland68645998015556111164192249317386
DJ,72795998015580118137
et7445599801555897
al.7570599801555581102
Secondary77005998015556119177242311380437474535
prevention82635998015567105165222283350387413481549
of8841599801556497
macrovascular896759980155102159216253319375434480537604630687723
events52206158015563120181249286334
in5583615801552592
patients57036158015570128166191253321358406
with61386158015591117156224
type6391615801553798169232
266526158015561
diabetes6741615801556994150220284322382429
in7198615801552592
the73196158015538106168
PROactive75156158015563125211269326368393451512
study8055615801554686154224280
(PROspective8364615801553295157243291360423481523549607667
pioglitazone9060615801556995163234259284323381433499568630
clinical5220631801555883108176201257315341
trial559063180155367399155181
in5800631801552390
macrovascular591963180155103160217253319376434481538605630687724
events):66716318015559116177245282330359378
a70786318015555
randomized7161631801553593161231299404429480541611
controlled78016318015554120188225262328355380442513
trial.8342631801553673100156182203
Lancet.85736318015555114182239298337359
2005;366:12791289.8960631801556012018524526232438544946952057263068952206479015563115175236253
20.52206636015767131156
Erdmann5404663901555995163267324392460
E,5892663901555980
Dormandy60016639015582151188294351418488545
JA,65746639015543114138
Charbonnel67406639015572139197233304373442509571597
B,7366663901556384
et7479663901556199
al.7607663901555782103
The77396639015558129191
effect7958663901556195130191249291
of82776639015567100
pioglitazone8406663901557096163234260284323381433500568630
on90656639015567135
recurrent9229663901553696154222258296356424461